✦ LIBER ✦

Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

✍ Scribed by Isani, S.S.; Rodriguez-Gabin, A.G.; Goldberg, G.L.; Horwitz, S.B.; McDaid, H.M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

253 Screening for PIK3CA, RAS, and RAF m

✍ F. Janku; A.M. Tsimberidou; I. Garrido-Laguna; D.S. Hong; A.M. Naing; G.S. Falch 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Cell Death Signaling in Cancer Biology a

✍ Johnson, Daniel E. 📂 Article 📅 2012 🏛 Springer New York ⚖ 1008 KB

402 Dual Inhibition of the MEK and the P

✍ Neuzillet, C.; Serova, M.; Raballand, A.; Astorgues-Xerri, L.; Riveiro, M.E.; de 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB